1V-LSD

1V-LSD (1-valeryl-LSD, also known as Valerie) is a synthetic psychedelic of the lysergamide family and an N1-acylated derivative of LSD featuring a valeryl (5-carbon) group at position 1 of the lysergamide nitrogen. Like other members of the 1-acyl LSD series, 1V-LSD is believed to function as a prodrug for LSD, with esterase-mediated cleavage of the valeryl ester releasing LSD in vivo. The subjective experience is therefore expected to be the full LSD experience, with the primary distinction being a delayed onset relative to LSD blotter.

Community reports describe 1V-LSD onset at approximately 75–100 minutes, somewhat longer than the 60–75 minutes typically reported for 1cP-LSD or 1P-LSD, which may reflect slower esterase hydrolysis of the larger valeryl group compared to shorter-chain acyl groups. Once fully active, the experience is described as indistinguishable from LSD, lasting 8–12 hours with the full character of LSD including visual phenomena, cognitive expansion, emotional amplification, and potential ego dissolution at sufficient doses.

1V-LSD appeared in the research chemical market in the early 2020s, as part of the continuing series of N1-acyl LSD analogs introduced in response to regulatory action against earlier members. It gained the informal name "Valerie" in community parlance, continuing the naming conventions established for other members of the series. Community experience is thinner than for 1P-LSD or 1cP-LSD, making the knowledge base for dosing, effects, and safety somewhat less mature.

Testing with Ehrlich reagent is essential before use. All LSD contraindications, harm reduction practices, and emergency protocols apply identically to 1V-LSD given the prodrug relationship.